ArticleFrontiers in oncology2025
Recognition of the novel items for prediction of bone metastasis in colorectal cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Role of Uric Acid-to-Albumin Ratio in Patients with Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore whether uric acid (UR), neutrophil/lymphocyte ratio (NLR) and uric acid/albumin ratio (UAR) can predict bone metastasis in colorectal cancer (CRC). Methods: A single-center retrospective study was conducted studying patients diagnosed with colorectal cancer attending The First Affiliated Hospital of Xian JiaoTong University between January 2016 and December 2021. Patients were categorized into groups with and without bone metastasis. Receiver operating characteristic (ROC) curve analysis assessed the diagnostic accuracy of CRC bone metastases, with subsequent combined ROC curve analysis. Differences among the AUCs were calculated and compared by Delong test. Logistic regression analysis was utilized to assess the impact of these parameters on CRC bone metastasis. Results: A total of 156 patients (32%) exhibited bone metastases from CRC. In these patients, levels of uric acid (UA), uric acid ratio (UAR), neutrophil-to-lymphocyte ratio (NLR), carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), and carbohydrate antigen 724 (CA724) were significantly elevated. The diagnostic performance of UA, UAR and NLR is surpassed that of traditional colorectal cancer markers. The area under the curve (AUC) for the combination UA, UAR and NLR with colorectal cancer tumor markers was significantly more effective in predicting bone metastasis ( Conclusions: UA, UAR and NLR serve as valuable makers for predicting bone metastases in patients with colorectal cancer. The integration of UA, UAR, NLR, CEA, CA199 and CA724 may enhance the prediction of bone metastases in colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.